Dr. Dujari is a board-certified neurologist and fellowship-trained neurohospitalist, specializing in the care of acute neurologic disorders. She practices at both Stanford Hospital and Stanford ValleyCare. She completed her medical training at Boston University, internal medicine preliminary year at California Pacific Medical Center, neurology residency at Stanford University, and neurohospitalist fellowship at Stanford University. She serves as the Neurology Resident & Fellow Wellness & Mentoring Committee faculty lead, the associated program director of the Stanford Neurohospitalist Fellowship, and the physician lead of the ValleyCare Neuroscience Quality Committee. She has a special interest in medical education and quality improvement.
For more information on the Stanford Neurohospitalist Program & Fellowship, please visit: https://med.stanford.edu/neurology/divisions/neurohospitalist.html
Clinical Assistant Professor, Neurology & Neurological Sciences
Board Certification: American Board of Psychiatry and Neurology, Neurology (2020)
Fellowship: Stanford University Dept of Neurology (2021) CA
Residency: Stanford University Neurology Residency (2020) CA
Internship: California Pacific Medical Center Dept of Medicine (2017) CA
Medical Education: Boston University School of Medicine (2016) MA
Residency, Stanford University Neurology Residency (2020)
Internship, California Pacific Medical Center Internal Medicine Residency (2017)
Medical Education, Boston University School of Medicine (2016)
Additional Clinical Info
- Inpatient Neurology Deaths and Factors Associated With Discharge to Hospice NEUROHOSPITALIST 2023
The Most Effective Interventions for Resident Well-being during the COVID-19 Pandemic
LIPPINCOTT WILLIAMS & WILKINS. 2021
View details for Web of Science ID 000729283603315
Administration of Dexamethasone for Bacterial Meningitis: An Unreliable Quality Measure.
2021; 11 (2): 101-106
To validate the use of administrative data to identify patients with bacterial meningitis and quantify the rate of dexamethasone administration as defined in the American Academy of Neurology Inpatient and Emergency Care Quality Measurement Set.The Vizient Clinical Data Base and Resource Manager was used to identify patients with International Classification of Diseases, Tenth Revision (ICD-10) codes for bacterial meningitis from October 2015 to June 2019. Chart review was performed on patients identified at a single quaternary-care hospital. The positive predictive value (PPV) of Vizient was determined. Demographic, clinical, and laboratory data were assessed using descriptive statistics.Of all hospitals that submitted complete data to Vizient during the study period, a median of 19 patients per hospital had ICD-10 codes for bacterial meningitis in the 45-month period. We identified 79 patients using Vizient at our institution of whom 69 had a diagnosis of bacterial meningitis confirmed by chart review (PPV = 87%). 15 patients were eligible to receive dexamethasone per the quality measurement set. Six of these patients (40%) received dexamethasone.It is feasible to use the Vizient Clinical Data Base and Resource Manager to identify patients with bacterial meningitis. Due to low prevalence across multiple institutions and high rate of exclusion criteria at our institution, this study suggests that the rate of dexamethasone administration in bacterial meningitis may be an unreliable indicator of quality of care provided by inpatient neurologists. The creation of a registry for hospitalized neurology patients could enhance development of future quality measures.
View details for DOI 10.1177/1941874420969556
View details for PubMedID 33791051
View details for PubMedCentralID PMC7958681
ACEP Guidelines on Acute Nontraumatic Headache Diagnosis and Management in the Emergency Department, Commentary on Behalf of the Refractory, Inpatient, Emergency Care Section of the American Headache Society.
The American College of Emergency Physicians (ACEP) published guidelines in July 2019 on the diagnosis and management of acute nontraumatic headaches in the emergency department, focusing predominantly on the diagnosis of subarachnoid hemorrhage and the role of imaging and lumbar puncture in diagnosis. The ACEP Clinical Policies document is intended to aide Emergency Physicians in their approach to patients presenting with acute headache and to improve the accuracy of diagnosis, while promoting safe patient care practices. The Clinical Policies document also highlights the need for future research into best practices to distinguish primary from secondary headaches and the efficacy and safety of current treatment options for acute headaches. The following commentary on these guidelines is intended to support and expand on these guidelines from the Headache specialists' perspective, written on behalf of the Refractory, Inpatient, Emergency Care section of the American Headache Society (AHS). The commentary have been reviewed and approved by Board of Directors of the AHS.
View details for DOI 10.1111/head.13744
View details for PubMedID 31944291
Utilization, yield, and accuracy of the FilmArray Meningitis/Encephalitis panel with diagnostic stewardship and testing algorithm.
Journal of clinical microbiology
Background: The impact of diagnostic stewardship and testing algorithms on utilization and performance of the FilmArray® Meningitis/Encephalitis (ME) Panel has received limited investigation.Methods: We performed a retrospective single-center cohort study assessing all individuals with suspected ME between February 2017 and April 2019 for whom the ME Panel was ordered. Testing was restricted to patients with cerebrospinal fluid (CSF) pleocytosis. Positive ME Panel results were confirmed before reporting through correlation with direct stain (Gram and Calcofluor white) and CSF Cryptococcal antigen or by repeat ME Panel testing. Outcomes included ME Panel test utilization rate, negative predictive value of non-pleocytic CSF samples, test yield and false-positivity rate, and time to appropriate de-escalation of acyclovir.Results: Restricting testing to pleocytic CSF samples reduced ME Panel utilization by 42.7% (263 vs 459 tests performed) and increased test yield by 61.8% (18.6% vs 11.5% positivity rate; P < 0.01) with application of criteria. The negative predictive value of normal CSF WBC for ME Panel targets was 100% (195/195) for non-viral targets and 98.0% (192/196) overall. All pathogens detected in non-pleocytic CSF samples were herpesviruses. Application of a selective testing algorithm based on repeat testing of non-viral targets avoided 75% (3/4) of false-positive results without generating false-negative results. Introduction of the ME panel reduced the duration of acyclovir treatment from an average of 66 hours (SD, 43) to 46 hours (SD, 36) (P = 0.03).Conclusions: Implementation of the ME Panel with restriction criteria and a selective testing algorithm for non-viral targets optimizes its utilization, yield and accuracy.
View details for DOI 10.1128/JCM.00311-20
View details for PubMedID 32493787
- Infected Implantable Pulse Generator NEUROHOSPITALIST 2019; 9 (3): 172–73
Making Well Neurologists: A Multifaceted Program for Neurology Trainee and Faculty Wellbeing
LIPPINCOTT WILLIAMS & WILKINS. 2019
View details for Web of Science ID 000475965902083
Design and Implementation of a Novel Acute Stroke Code for the Extended Window of Endovascular Treatment
LIPPINCOTT WILLIAMS & WILKINS. 2018
View details for Web of Science ID 000453090803006